China Biopharma announced recently that it was getting out of the vaccine business, because the vaccine market in China has too many players, making the business too competitive and causing the margins to thin to unacceptable levels. Instead, the company will seek specialty pharmaceutical products as a long-term project. In the short term, it will build up its distribution business and increase its ownership in its subsidiary companies. Meanwhile, the financial situation of China Biopharma remains dire.  More details...

Stock Symbol: (OTCBB: CBPC)